First of all I have been invested and followed VBLT for the last3 years. More recently followed it daily (and made some calculations) as we get closer to GBM ph3 results Simply I have not written on this board until recently.
Secondly the enrollment was completed in December 2016 (last two patients), effectively 99% completed in November 2016 (as stated by CEO). The two arms enrollment was completed almost simultaneously as patients are randomly assigned and the end result is 50%-50%, keeping a constant balance between the two arms (it appears you are not experienced enough about clinical trials and randomization, are you?)
The 105th event is irrelevant when it happened, who cares?
Based on the above the minimum composite rate reached so far is pretty solid, and if Avastin is behaving like historical (that is the only big assumption I am making), then VBL111 is already showing an improvement vs Avastin monotherapry.
You are asking when the 189th event will happen and what will be the split between the two arms. If you ask these questions I start to think you have not understood much about my points and that you never will, regardless of how many times I explain it, but really it doesn't matter.
At least one of this board has understood my point. Oren, a smart guy I think
News 
Market Data 
Discover 
